Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis, finds study

A study involving over 400,000 men aged 50-69 found that a single invitation to a PSA blood test for prostate cancer screening had a small impact on reducing deaths, but also led to overdiagnosis and missed detection of aggressive cancers. The results showed that 1 in 6 cancers detected by the screening were overdiagnosed, leading to unnecessary treatment with potential side effects. Cancer Research UK emphasizes the importance of listening to your body and seeking medical advice if you notice any changes. Despite improvements in diagnosing and treating prostate cancer, more research is needed to accurately detect aggressive cancers early.

Source link

error: Content is protected !!